{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:13:10Z","timestamp":1778814790215,"version":"3.51.4"},"reference-count":15,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003197","name":"AIFA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.cllc.2014.09.001","type":"journal-article","created":{"date-parts":[[2014,9,28]],"date-time":"2014-09-28T13:02:49Z","timestamp":1411909369000},"page":"67-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Italian Multicenter Phase III Randomized Study of\u00a0Cisplatin\u2013Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive Stage Small Cell Lung Cancer: Treatment Rationale and Protocol Design of the GOIRC-AIFA FARM6PMFJM Trial"],"prefix":"10.1016","volume":"16","author":[{"given":"Marcello","family":"Tiseo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Boni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Ambrosio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Camerini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Giuseppa","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Editta","family":"Baldini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saverio","family":"Cinieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Zanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efisio","family":"Defraia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodolfo","family":"Passalacqua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucio","family":"Crino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Dazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmelo","family":"Tibaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianni M.","family":"Turolla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vito","family":"D'Alessandro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Zilembo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferdinando","family":"Riccardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Ardizzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2014.09.001_bib1","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1200\/JCO.2005.04.4859","article-title":"Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the Surveillance, Epidemiologic, and End-Results database","volume":"24","author":"Govindan","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2014.09.001_bib2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1556-0864(15)31579-3","article-title":"A\u00a0review of first-line treatment for small-cell lung cancer","volume":"1","author":"Murray","year":"2006","journal-title":"J\u00a0Thorac Oncol"},{"issue":"suppl 6","key":"10.1016\/j.cllc.2014.09.001_bib3","doi-asserted-by":"crossref","first-page":"vi99","DOI":"10.1093\/annonc\/mdt178","article-title":"Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Fr\u00fch","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2014.09.001_bib4","first-page":"538","article-title":"The development of targeted therapy in small cell lung cancer","volume":"5","author":"Zhang","year":"2013","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.cllc.2014.09.001_bib5","first-page":"669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat\u00a0Med"},{"key":"10.1016\/j.cllc.2014.09.001_bib6","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S1010-7940(02)00112-4","article-title":"Small cell lung carcinoma (SCLC): the\u00a0angiogenic phenomenon","volume":"21","author":"Lucchi","year":"2002","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.cllc.2014.09.001_bib7","first-page":"37","article-title":"Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in small cell and non\u2013small-cell lung carcinoma","volume":"19","author":"Stefanou","year":"2004","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.cllc.2014.09.001_bib8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1200\/JCO.2009.24.7353","article-title":"Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab","volume":"28","author":"Spigel","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2014.09.001_bib9","doi-asserted-by":"crossref","first-page":"6006","DOI":"10.1200\/JCO.2009.23.7545","article-title":"Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501","volume":"27","author":"Horn","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2014.09.001_bib10","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1200\/JCO.2010.29.3423","article-title":"Randomized phase II study of\u00a0bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial","volume":"29","author":"Spigel","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2014.09.001_bib11","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1097\/JTO.0b013e3181bbc540","article-title":"Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer","volume":"4","author":"Spigel","year":"2009","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2014.09.001_bib12","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1200\/JCO.2011.35.6923","article-title":"Cisplatin, irinotecan, and bevacizumab for\u00a0untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study","volume":"29","author":"Ready","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.cllc.2014.09.001_bib13","article-title":"Randomized phase II\u2013III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial","volume":"32","author":"Pujol","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.cllc.2014.09.001_bib14","article-title":"Phase II study of oral topotecan plus bevacizumab (topo-bev) for second-line treatment of small cell lung cancer (SCLC)","volume":"28","author":"Waterhouse","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2014.09.001_bib15","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/JTO.0b013e3181f77b6e","article-title":"Paclitaxel plus bevacizumab in patients with\u00a0chemosensitive relapsed small cell lung cancer: a safety, feasibility, and\u00a0efficacy study from the Hoosier Oncology Group","volume":"5","author":"Jalal","year":"2010","journal-title":"J\u00a0Thorac Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730414001843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730414001843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:04:37Z","timestamp":1761505477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730414001843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S1525730414001843"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2014.09.001","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Italian Multicenter Phase III Randomized Study of\u00a0Cisplatin\u2013Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive Stage Small Cell Lung Cancer: Treatment Rationale and Protocol Design of the GOIRC-AIFA FARM6PMFJM Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2014.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}